Ramoplanin: A novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 3, 2003, Pages

  Montecalvo, Marisa A ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; VANCOMYCIN;

ABDOMINAL PAIN; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG STRUCTURE; DYSPEPSIA; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FLATULENCE; GASTROINTESTINAL TRACT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DEPSIPEPTIDES; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PEPTIDES, CYCLIC; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 0038601521     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Murray, B. E. (2000). Vancomycin-resistant enterococcal infections. New England Journal of Medicine 342, 710-21.
2. Hospital Infection Control Practices Advisory Committee. (1995). Recommendations for preventing the spread of vancomycin resistance. Infection Control and Hospital Epidemiology 16, 105-13.
3. Linden, P., Moellering, R. C., Jr, Wood, C. A., Rehm, S. J., Flaherty, J., Bompart, F. et al. (2001). Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clinical Infectious Diseases 33, 1816-23.
4. Pai, M. P., Rodvold, K. A., Schreckenberger, P. C., Gonzales, R. D., Petrolatti, J. M. & Quinn, J. P. (2002). Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clinical Infectious Diseases 35, 1269-72.
5. Centers for Disease Control and Prevention. (2002). Vancomycin-resistant Staphylococcus aureus - Pennsylvania. Morbidity and Mortality Weekly Report 51, 902.
6. Boyce, J. M., Opal, S. M., Chow, J. W., Zervos, M. J., Potter-Bynoe, G., Sherman C. B. et al. (1994). Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. Journal of Clinical Microbiology 32, 1148-53.
7. Quale, J., Landman, D., Sauraina, G., Atwood, E., DiTore, V. & Patel, K. (1996). Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clinical Infectious Diseases 23, 1020-5.
8. Donskey, C. J., Chowdhry, T. K., Hecker, M. T., Hoyen, C. K., Hanrahan, J. A., Hujer, A. M. et al. (2000). Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. New England Journal of Medicine 343, 1925-32.
9. Montecalvo, M. A., Jarvis, W. R., Uman, J., Shay, D. K., Petrullo, C., Rodney, K. et al. (1999). Infection control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Annals of Internal Medicine 131, 269-72.
10. Reynolds, P. E. & Somner, E. A. (1990). Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Under Experimental and Clinical Research 16, 385-9.
11. Jones, R. N. & Barry, A. L. (1989). In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagnostic Microbiology and Infectious Disease 12, 279-82.
12. Collins, L. A., Eliopoulos, G. M., Wennersten, C. B., Ferraro, M. J. & Moellering, R. C., Jr (1993). In vitro activity of ramoplanin against vancomycin-resistant Gram-positive organisms. Antimicrobial Agents and Chemotherapy 37, 1364-6.
13. Johnson, C. C., Taylor, S., Pitsakis, P., May, P. & Levison, M. E. (1992). Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrobial Agents and Chemotherapy 36, 2342-5.
14. White, D. J., Visweswaran, V., So, W., Hurst, M. A. & Gedde, M. M. (2000). Resistance profile of ramoplanin, a novel glycolipodepsipeptide with activity selective for Gram-positive bacteria [poster]. First International Symposium on Resistant Gram-Positive Infections. 3-5 December 2000, San Antonio, TX, USA.
15. Citron, D. M., Merriam, C. V., Tyrrell, K. L., Warren, Y. A., Fernandez, H. & Goldstein, E. J. C. (2003). Comparative in vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrobial Agents and Chemotherapy, in press.
16. de Lalla, F., Romeo, B., Nicolin, R., Pallizzer, G., Merati, R. & Riva, E. (1995). Oral ramoplanin single dose administration in pseudomembranous colitis. Canadian Journal of Infectious Diseases 6, Suppl. 5, 452C.
17. Wong, M. T., Kauffman, C. A., Standiford, H. C., Linden, P., Fort, G., Fuchs, H. J. et al. (2001). Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastro-intestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clinical Infectious Diseases 33, 1476-82.
18. Baden, L. R., Critchley, I. A., Sahm, D. F., So, W., Gedde, M., Porter, S. et al. (2002). Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. Journal of Clinical Microbiology 40, 1160-3.